Survivor Videos
957 articles
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Can a Pancreatic Cancer Screening Test Become a Reality?
Dr. Felice Schnoll-Sussman discusses screening options for pancreatic cancer and criteria for people who might want to get screened.
PRECEDE Trial Sets Survival Rate Goal
Dr. Raymond Wadlow explains how earlier detection of high-risk people is key the PRECEDE trial’s goal to increase pancreatic cancer survival rates.
A Year in Review: 2022 in Research
What progress was made in pancreatic treatment and screening? Learn about the major pancreatic cancer developments of 2022.
The Future of Pancreatic Cancer Treatment
Dr. Anil Rustgi discusses the latest developments in pancreatic cancer treatment and the direction of current research in early detection.
Aiming to Improve Immunotherapy for Pancreatic Cancer
Dr. Deirdre Cohen discusses clinical trials that aim to improve the effectiveness of immunotherapy for pancreatic cancer.
Putting the Immune System on the Offensive
A discussion of immunology in cancer treatment, focusing on the work of Elizabeth Jaffe, M.D., and her cancer vaccine and checkpoint inhibitors.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.
New Neoadjuvant Treatment in Trials
Dr. Brian Wolpin provides an analysis of the latest data on a new neoadjuvant treatment for tumors that can be removed.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
A Look Back at Research in 2024
Research in 2024 focused on personally tailored treatments, countering the most difficult effects of pancreatic cancer, and clinical trials.
Testing the Addition of a New Drug to Radiation Therapy for Localized Pancreatic Cancer
In combination with radiation treatment, researchers are testing a new drug that causes DNA damage to make that treatment more effective.
Research and Other Highlights from the 2023 AACR Annual Meeting
The 2023 AACR meeting focused on the latest research into KRAS, other immunotherapy approaches, and honored Dr. Elizabeth Jaffee.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.